Law Schedule of Classes

NOTE: Course offerings change. Classes offered this semester may not be offered in future semesters.

Apart from their assigned mod courses, 1L students may only enroll in courses offered as 1L electives. A complete list of these courses can be found on the 1L Elective Listings page. 1L students must use the 1L class number listed on the course description when enrolling.


276.66 sec. 001 - Topics in Pharmaceutical Policy: the Case of Biotherapeutics (Spring 2021)

Instructor: Rachel Zuraw  (view instructor's teaching evaluations - degree students only)
View all teaching evaluations for this course - degree students only

Units: 1
Grading Designation: Credit Only
Mode of Instruction: Remote Instruction

Meeting:

    Th 3:35 PM - 5:25 PM
    Location: Internet/Online
    From January 21, 2021
    To March 04, 2021

Course Start: January 21, 2021
Course End: March 04, 2021
Class Number: 32091

Enrollment info:
Enrolled: 12
Waitlisted: 0
Enroll Limit: 24
As of: 05/08 05:45 AM


Biotherapeutics, which has been widely hailed as the fastest-growing sector in the pharmaceutical industry, have been much in the news lately. Revenues are already in the hundreds of billions, and given that biologics (treatments derived from living cells) make up more than 50% of drugs currently in development, this is only predicted to increase. Furthermore, the race to develop treatments and vaccines to counter the COVID-19 global pandemic has started the world talking about biologics like monoclonal antibodies.

So, why have this course at a law school? Biologics are taking off at a time when we are wrestling with global intellectual property rights in the pharmaceutical industry. In this course we will use case studies from the United States, the European Union, and India to explore the impact of the gaps, conflicts, and overlaps in different countries’ patent systems and marketing approvals on the pricing and accessibility of pharmaceutical products. Students will learn to consider and compare different methods of intellectual property protection for biologic drugs, as well as how to apply ethical frameworks to consider their impact.

This course has no prerequisites; there will be an overview at the outset of the patentability of biologic products that will provide a sufficient basis for the expected level of discussion. The course is particularly designed to benefit and seek input from students with international practice experience, though both LL.M. and J.D. students are encouraged to enroll.

Professor Zuraw earned her J.D. and Master's in Bioethics from the University of Pennsylvania, and has taught courses in law and bioethics at Drexel University Thomas R. Kline School of Law and the University of Pennsylvania School of Arts and Sciences. She subsequently practiced at firms in the Bay Area for several years in the areas of health care and complex intellectual property litigation.


Real-time attendance at the first class is mandatory for all currently enrolled and waitlisted students; any currently enrolled or waitlisted students who are not present on the first day of class (without prior permission of the instructor) will be dropped. The instructor will continue to take attendance throughout the add/drop period and anyone who moves off the waitlist into the class must continue to attend or have prior permission of the instructor in order not to be dropped.


Exam Notes: (T) Course ends in a final practice trial, arguments, or other presentation (e.g. Powerpoint)
Course Category: Intellectual Property and Technology Law

If you are the instructor or their FSU, you may add a file like a syllabus or a first assignment to this page.

Readers:
No reader.

Books:
Instructor has indicated that no books will be assigned.

Go to Course Search